(Q43901434)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Pancras C.W. Hogendoorn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

author name string

L Svancárová

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

I R Judson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Q G C M van Hoesel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A T van Oosterom

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

A le Cesne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

H J Keizer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

C Hermans

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

M van Glabbeke

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

J Verweij

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

O S Nielsen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 March 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

556-559

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872349%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy of advanced soft-tissue sarcomas in adults

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

The role of gemcitabine in the treatment of other tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

The role of chemotherapy in the treatment of adult soft tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900408-7

7 January 2021